Sustainable Nanotechnologies Derived from Renewable Resources for Advanced Drug Design, Delivery and Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 861

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemistry, Laboratory of Chemistry of Natural Products, Federal University of Maranhão, São Luís 65080-805, Brazil
Interests: combination therapy; nanotechnology; nanomedicine; photodynamic therapy; natural products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Sustainable nanotechnologies derived from renewable biological resources have emerged as a strategic approach to the development of advanced drug delivery systems, integrating therapeutic efficiency, safety, and environmental responsibility. The incorporation of natural polymers, renewable bioactive molecules, and eco-friendly synthetic processes enables the design of nanoarchitectures with high biocompatibility, functional versatility, and superior pharmaceutical performance. In parallel, the use of green materials and low-impact synthetic pathways reduces chemical waste, energy consumption, and dependence on petrochemical sources. This Special Issue aims to gather scientific contributions on topics ranging from the molecular design to the therapeutic application of sustainable nanomaterials, including nanoemulsions, nanogels, hybrid nanocarriers, green-synthesized metallic nanoparticles, natural photosensitizing systems, and platforms for combined therapies. Emphasis will be placed on studies demonstrating advances in the mechanisms of action, physicochemical modeling, nano–bio interactions, and preclinical evaluation of sustainable nanomaterials, and their impact on oncology, infectious diseases, inflammation, and parasitic disorders. By promoting integrated discussions across green chemistry, pharmaceutical nanotechnology, and translational medicine, this Special Issue seeks to encourage the development of innovative, safe, and sustainable solutions to current challenges in drug design, delivery, and therapy.

Dr. Renato Sonchini Gonçalves
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sustainable nanotechnology
  • renewable resources
  • green synthesis
  • drug delivery systems
  • natural products
  • nanomedicine
  • photodynamic therapy
  • advanced therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

34 pages, 4672 KB  
Review
Renewable Feedstock Nanocarriers for Drug Delivery: Evidence Mapping and Translational Readiness
by Renato Sonchini Gonçalves
Pharmaceutics 2026, 18(4), 407; https://doi.org/10.3390/pharmaceutics18040407 - 25 Mar 2026
Viewed by 584
Abstract
Sustainable nanotechnologies derived from renewable resources are increasingly being positioned at the interface of green chemistry, advanced drug delivery, and translational pharmaceutics. Over the past decade, lignocellulosic nanomaterials, chitin/chitosan platforms, polysaccharide-based nanogels and nano-enabled hydrogels, lignin- and polyphenol-derived nanostructures, and bio-based lipid nanocarriers [...] Read more.
Sustainable nanotechnologies derived from renewable resources are increasingly being positioned at the interface of green chemistry, advanced drug delivery, and translational pharmaceutics. Over the past decade, lignocellulosic nanomaterials, chitin/chitosan platforms, polysaccharide-based nanogels and nano-enabled hydrogels, lignin- and polyphenol-derived nanostructures, and bio-based lipid nanocarriers have been engineered through progressively eco-efficient routes, including solvent-minimized self-assembly, nanoprecipitation, spray drying, hot-melt extrusion, and microfluidic-assisted fabrication. This work provides a structured evidence map of nano-enabled drug delivery and therapeutic platforms derived from renewable biological resources. Specifically, we aim to (i) identify and classify nanoplatform classes and renewable feedstocks; (ii) summarize reported pharmaceutical critical quality attributes (CQAs) and performance and safety endpoints; and (iii) appraise how “renewability” and “green” claims are evidenced (feedstock origin vs. process sustainability) and how frequently translational readiness factors (scalability, quality control, regulatory alignment) are addressed. We critically compare renewable and conventional nanomaterial platforms across key translational dimensions, including carbon footprint, batch consistency, biodegradability, functional tunability, safety/persistence, and scale-up maturity. Finally, we delineate a practical translational pathway—from biomass sourcing and fractionation to nanoformulation, characterization/stability, and GMP scale-up—highlighting cross-cutting enablers such as lifecycle assessment, EHS/toxicology risk assessment, quality-by-design, and regulatory alignment. Collectively, the evidence supports renewable nanomaterials as viable, scalable candidates for next-generation therapeutics, provided that variability control, standardized characterization, and safety-by-design principles are embedded early in development. Full article
Show Figures

Graphical abstract

Back to TopTop